CEVEC Pharmaceuticals GmbH (CEVEC) announced the signing of a license agreement with Evox Therapeutics, Ltd. (Evox) for the development and commercialization of therapeutic exosomes using CEVEC’s proprietary CAP technology.
The license agreement is the result of an ongoing collaboration between Evox and CEVEC which has demonstrated the utility of CEVEC’s CAP technology to produce exosomes. Evox intends to develop CAP-derived exosomes for several disease areas and indications. As part of the agreement, CEVEC will be eligible for milestone payments and royalties. Further financial details of the agreement were not disclosed.
“We are delighted that Evox, a leader in the exosome therapeutics space, has chosen our CAP cell line and technology for some of their exosome programmes” said Dr. Nicole Faust, CEO of CEVEC. “Over the last years, our CAP cells have already shown perfect suitability for the production of various complex therapeutics, including recombinant proteins and viral vectors for gene therapy applications. With CAP cells for exosomes, we are now enabling pharma and biotech companies to enter into a new field of promising therapeutic modalities and targeted drug delivery.”
Evox Therapeutics is a privately held, Oxford-based biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop an entirely new class of biotherapeutics.
CEVEC is a leading provider of high-performance cell technology for the manufacturing of advanced bio-therapeutics from R&D to manufacturing scale.